Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec and Interprotein Corporation have signed a collaboration agreement on an Interleukin 6 inhibitors program for the development of drugs treating inflammatory diseases.
Subscribe to our email newsletter
Interleukin 6 (IL-6) is a crucial cytokine involved in the onset and progression of inflammatory diseases such as rheumatoid arthritis and cachexia.
Based on in silico drug design, Interprotein discovered a number of hit molecules. On the basis of these structures Evotec will use their expertise in medicinal chemistry, computational chemistry and profiling to fully optimize the compounds and to develop potent inhibitors for IL-6.
“We believe that orally available drugs have the potential to supersede antibody therapy and furthermore, we hope that this program will prove that small molecule compounds may have the potential to inhibit such protein-protein interactions,” commented Mr Masato Hosoda, president and CEO of Interprotein.